



Docket No: AM100146 C2
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Magid A. Abou-Gharbia et al.
Application No.: 10/726,168 Group No.: 1617
Filed: December 2, 2003 Examiner: R. Travers
For: Methods for the Treatment and Prevention of Neurodegenerative
Conditions
Confirmation No.: 4143
Customer Number: 25291

Mail Stop Missing Parts
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

AMENDMENT

In the specification

Please delete page 4, lines 6-12.

Replace line 31 on page 7 with the following line:

For experiments where test compound was examined, ~~drug~~ 10, 100 or 1000nM adatanserin was added one fraction prior to the induction of ischemia dissolved in aglycemic Krebs buffer.

At page 8, line 12, delete "Results are presented in Figure 1."

Replace line 14 on page 8 with the following line:

~~As shown in Figure 1, adatanserin~~ Adatanserin significantly reduced azide-induced ischemic efflux of glutamate in rat hippocampal slices.


CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU733072755US addressed to MS Missing Parts, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date

5-17-04

John R. Barker

A handwritten signature in cursive script, reading "Rebecca R. Barrett", is written over a horizontal line.

Rebecca R. Barrett
May 17, 2004
Attorney for Applicants
Reg. No. 35,152

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8607